Head-to-head · WeighScore
HealthSource vs Lttl
By GLP-1 ScorecardUpdated
Score comparison
HealthSource has the higher recorded score — 71.2/100 to 63.5/100.
HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | HealthSource | Lttl |
|---|---|---|
| WeighScore | 71.2/100 | 63.5/100 |
| Grade | C | C |
| Site position | #105 | #209 |
| Semaglutide | $199/mo (all doses, compounded) | $99/mo monthly auto-refill; $89/mo equivalent billed $1,068 annually (confirm supply/renewal) |
| Tirzepatide | $299/mo (all doses, compounded) | $149/mo monthly auto-refill; $139/mo equivalent billed $1,668 annually (confirm supply/renewal) |
| Coverage | All 50 states | Provider claims 50 states + DC; treatment availability varies |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #105 · C
Strengths
- Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
- 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
- Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
- Subscription auto-refund if monthly reassessment is not completed
- Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping
What to consider
- No physician names or clinical leadership disclosed on public pages
- No LegitScript certification found
- 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
- Labs not mentioned on any product page — baseline bloodwork protocol unknown
- WooCommerce e-commerce storefront may feel more transactional than clinical
Site position #209 · C
Strengths
- Public ordinary monthly injection rates of $99 semaglutide and $149 tirzepatide, with longer-plan charges disclosed separately
- The plan selector identifies supply lengths, including four weeks for monthly auto-refill and 52 weeks annually
- Four possible dispensing pharmacies are named in the terms, without an individual assignment established
- Microdose injection and oral-tablet selector entries provide additional options to discuss with a clinician; availability and clinical suitability require confirmation
What to consider
- Monthly, quarterly and six-month supply labels do not align with calendar-month language; confirm actual refill and debit intervals
- Medical-rejection refund language conflicts with consultation-fee retention wording
- Terms use medical intake as a nonrefund boundary, while support uses pharmacy processing/shipping; refund deadlines also differ
- The assigned treating practice, prescriber and actual dispensing location remain unestablished
- Branded-service exceptions are described, but no available brand-specific prescription or price was established
- A 48-hour shipping headline differs from the policy estimate of two to five business days processing plus three to seven in transit
Featured provider
Lttl
Lttl scores 63.5/100 (C). Lttl publishes monthly and longer compounded-injection offers plus a low-dose and oral menu; compare the actual charge and supply interval because annual equivalents and four-week labels describe different commitments.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.